4D Molecular Therapeutics (FDMT) Other Non-Current Assets (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Other Non-Current Assets data on file, last reported at $9.9 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 39.97% year-over-year to $9.9 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 39.97% increase from a year earlier, with the FY2025 full-year figure at $9.2 million, up 115.63% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $9.9 million, up from $9.2 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for FDMT reached as high as $9.9 million in Q1 2026 and fell as low as $682000.0 in Q3 2023.
• Historically, Other Non-Current Assets has averaged $3.7 million across 5 years, with a median of $1.3 million in 2023.
• Across the five-year window, Other Non-Current Assets plunged 38.81% in 2024 and jumped 813.49% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $1.1 million in 2022, then sank by 36.67% to $684000.0 in 2023, then surged by 522.95% to $4.3 million in 2024, then jumped by 115.63% to $9.2 million in 2025, then gained by 7.29% to $9.9 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $9.9 million in Q1 2026, $9.2 million in Q4 2025, and $9.4 million in Q3 2025.